A Randomized, Open-Label Study Comparing the Effects of Olanzapine Pamoate Depot With Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia.
Phase of Trial: Phase III
Latest Information Update: 26 Feb 2017
At a glance
- Drugs Olanzapine (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 02 Jun 2011 Remission results presented at the 10th World Congress of Biological Psychiatry.
- 01 Sep 2010 Results were presented at the 23rd Annual Congress of the European College of Neuropsychopharmacology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History